Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia...
(Source: Alkermes plc) Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society Conference - Results From Positive Phase 2 Study of ALKS 3831 for the...
View ArticleAlkermes to Present Data on ALKS 5461 at Upcoming American Society of...
(Source: Alkermes plc) Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting - Company to Host Webcast Presentation and Conference Call on...
View ArticleAlkermes to Present Data on ALKS 5461 at Upcoming American Society of...
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting — Company to Host Webcast Presentation and Conference Call on Wednesday, June 1 — —...
View ArticleFDA Issues Complete Response Letter for Digital Medicine New Drug Application...
(Source: Otsuka America Pharmaceutical Inc) Tokyo, Japan, and Redwood City, Calif. - April 26, 2016 -Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that...
View ArticleAllergan and Richter Provide Update on Cariprazine Program (Allergan plc)
(Source: Allergan plc) DUBLIN, Ireland and BUDAPEST, Hungary, Aug. 5, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Gedeon Richter Plc., today provided a...
View ArticleAlkermes Submits Supplemental New Drug Application to FDA for Two-Month...
(Source: Alkermes plc) Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia -- Potential New Offering Would Expand Range of...
View ArticleAlkermes Submits Supplemental New Drug Application to FDA for Two-Month...
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia –– Potential New Offering Would Expand Range of ARISTADA Doses to Three...
View ArticleUS FDA approves labeling update of Rexulti® (brexpiprazole) for maintenance...
(Source: H Lundbeck A/S) Valby, Denmark, 2016-09-24 00:30 CEST (GLOBE NEWSWIRE) -- Labeling update includes clinical data on use of Rexulti in adult patients with schizophrenia in the maintenance phase...
View ArticleUS FDA approves labeling update of Rexulti® (brexpiprazole) for maintenance...
Valby, Denmark, 2016-09-24 00:30 CEST (GLOBE NEWSWIRE) -- Labeling update includes clinical data on use of Rexulti in adult patients with schizophrenia in the maintenance phase of treatment Approval...
View ArticleTeva Launches Generic Abilify® Tablets in the United States (Teva...
(Source: Teva Pharmaceuticals USA Inc) Teva Launches Generic Abilify® Tablets in the United States JERUSALEM--(BUSINESS WIRE)--Apr. 28, 2015-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today...
View ArticleNew Study Published in JAMA Psychiatry Found Three-Month Paliperidone...
TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients...
View ArticleUPDATE 2-Alkermes to seek schizophrenia drug approval after trial success
* To apply for U.S. marketing approval in the third quarter * Drug reduced severity of schizophrenia symptoms in trial * Shares rise as much as 11 pct (Adds CEO comments from conference call,...
View ArticleAlkermes shares surge as trials prove potential for new schizophrenia drug
Shares in Irish drug company Alkermes jumped over 10 per cent yesterday after it announced plans to seek US marketing approval for its experimental schizophrenia drug. The move came as the company...
View ArticleYoung adult patients* with schizophrenia show improved functioning and...
(Source: H Lundbeck A/S) Valby, 2015-06-23 17:47 CEST (GLOBE NEWSWIRE) -- For non-US media only • A newly released pre-specified subgroup analysis from the QUALIFY** study shows that younger adult...
View ArticleAripiprazole once-monthly shows superior effectiveness to paliperidone...
(Source: H Lundbeck A/S) The head-to-head QUALIFY study compared the effectiveness of aripiprazole once-monthly to paliperidone palmitate once-monthly in adult patients with schizophrenia Patients...
View ArticleTeva Launches Generic Abilify® Tablets in the United States (Teva...
(Source: Teva Pharmaceuticals USA Inc) Teva Launches Generic Abilify® Tablets in the United States JERUSALEM--(BUSINESS WIRE)--Apr. 28, 2015-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today...
View ArticleAllergan and Gedeon Richter Plc. to Present Data on Cariprazine at the...
(Source: Allergan plc) DUBLIN and BUDAPEST, Hungary, May 12, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that nine posters highlighting additional scientific...
View ArticleAlkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia...
(Source: Alkermes plc) Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society Conference - Results From Positive Phase 2 Study of ALKS 3831 for the...
View ArticleAlkermes to Present Data on ALKS 5461 at Upcoming American Society of...
(Source: Alkermes plc) Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting - Company to Host Webcast Presentation and Conference Call on...
View ArticleAlkermes to Present Data on ALKS 5461 at Upcoming American Society of...
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting — Company to Host Webcast Presentation and Conference Call on Wednesday, June 1 — —...
View Article